Targeting mitochondria to treat heart failure
Official title: Synergistically Target Mitochondria for Heart Failure Treatment
Funded at Ohio State University · NIH-10825544 · Data updated 2026-11-12
This study is looking at how problems with tiny energy factories in heart cells, called mitochondria, can lead to heart failure, and it's working on new treatments that could help keep these factories running well and protect the heart from damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $588,719 |
| NIH project number | 5R01HL160690-02 |
| Project ID | NIH-10825544 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with heart failure who may benefit from innovative mitochondrial-targeted therapies.
✕Less likely to help
Patients with heart failure caused by non-mitochondrial factors may not receive benefit from this research.
What this research studies
This research investigates the role of mitochondria in heart failure, focusing on how defects in mitochondrial function contribute to the disease. The approach aims to develop therapies that can both preserve mitochondrial membrane potential and reduce harmful reactive oxygen species in heart cells. By using advanced techniques to assess mitochondrial function in live animals, the research seeks to identify effective treatments that could improve heart health and patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve the treatment of heart failure.
How similar studies have gone: While antioxidant therapies have shown promise in preclinical studies, this approach of synergistically targeting mitochondrial function is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Zhou, Lufang — Ohio State University
- Study coordinator: Zhou, Lufang
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.